Leronlimab PRO 140|cas:674782-26-4|西域试剂

Leronlimab PRO 140,95.00%

产品编号：Bellancom-P99697| CAS NO：674782-26-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99697	￥2800.00	杭州北京（现货）
Bellancom-P99697	￥8000.00	杭州北京（现货）
Bellancom-P99697	￥12800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Leronlimab PRO 140

产品介绍

Leronlimab (PRO 140) 是一种人源化 IgG4 抗 CCR5 单克隆抗体。leronlimumab 抑制 CCR 介导的 HIV-1 病毒和小鼠肿瘤模型肺转移。Leronlimab 可用于 HIV 非酒精性脂肪性肝炎 (NASH) 和癌症的研究。

生物活性

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.

体外研究

Leronlimab (1-140 mg/mL) 结合 CCR5 阳性细胞高达 98%。
Leronlimab (80-1750 μg/mL) 阻断 MDA-MB-231 细胞中 CCL5，CCL3 和 CCL4 诱导的钙反应。
Leronlimab (175 和 350 mg/mL) 阻断 MDA-MB-231 细胞侵袭。
Leronlimab (10 μg/mL；72 小时) 增强 doxorubicin 对 MDA-MB-231 细胞的细胞毒性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	MDA-MB-231 cell line
Concentration:	10 μg/mL
Incubation Time:	72 hours
Result:	Increased the cells killing effect induced by doxorubicin.

体内研究
(In Vivo)

Leronlimab (2 mg；腹腔注射，每周 2 次) 降低小鼠异种移植模型的肺转移情况。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NCI Athymic nu/nu nude mice with MB-MDA-231 cells expressing Luc2-eGFP injection
Dosage:	2 mg
Administration:	Intraperitoneal injection; 2 mg, twice a week
Result:	Reduced the volume of pulmonary metastases at 8 weeks.

体内研究

Leronlimab (2 mg；腹腔注射，每周 2 次) 降低小鼠异种移植模型的肺转移情况。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NCI Athymic nu/nu nude mice with MB-MDA-231 cells expressing Luc2-eGFP injection
Dosage:	2 mg
Administration:	Intraperitoneal injection; 2 mg, twice a week
Result:	Reduced the volume of pulmonary metastases at 8 weeks.

体内研究

Leronlimab (2 mg；腹腔注射，每周 2 次) 降低小鼠异种移植模型的肺转移情况。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NCI Athymic nu/nu nude mice with MB-MDA-231 cells expressing Luc2-eGFP injection
Dosage:	2 mg
Administration:	Intraperitoneal injection; 2 mg, twice a week
Result:	Reduced the volume of pulmonary metastases at 8 weeks.